GlassScriptPhysician profile
Jennifer Linford
NPI 1215608716
$2,775.75
in general payments reported to CMS, 2019-2025
11 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $500 · 2022: $179 · 2023: $494 · 2024: $503 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,097.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,102.18 | 2023-2025 | Inspire |
| Aerin Medical INC. | $563.21 | 2021-2023 | |
| Vertex Pharmaceuticals Incorporated | $474.41 | 2025 | |
| Stryker Corporation | $164.13 | 2024-2025 | Scopis Ent, N/A |
| Genzyme Corporation | $121.62 | 2025 | |
| Smith+Nephew, INC. | $103.51 | 2022 | |
| Novo Nordisk INC | $102.75 | 2025 | Ozempic |
| Tactile Systems Technology INC | $75.89 | 2022-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Astrazeneca Pharmaceuticals LP | $30.95 | 2025 | Tezspire |
| Atos Medical INC | $23.21 | 2024 | Provox Life Home Hme |
| Glaxosmithkline, LLC. | $13.89 | 2023 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Linford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.